LakeShore Biopharma Finalizes Going-Private Terms at Drastically Reduced Price of $0.066 Per Share Amid Massive Liabilities

summarizeSummary

LakeShore Biopharma has filed definitive documents for its amended going-private transaction, confirming a per-share consideration of $0.066, a substantial reduction from the original $0.90 offer due to massive arbitral award liabilities.

check_boxKey Events

• Going-Private Transaction Finalized at Reduced Price

  The company has finalized the terms of its going-private transaction, offering unaffiliated shareholders $0.066 in cash per share. This is a drastic reduction from the initial offer of $0.90 per share made on November 4, 2025, and follows the amended merger agreement dated April 29, 2026.

• Massive Arbitral Award Liabilities Cited for Price Reduction

  The significant reduction in the merger consideration is primarily attributed to approximately RMB576.5 million (US$84.3 million) in arbitral awards against the company's subsidiaries. This liability substantially exceeds the company's current equity value, indicating severe financial distress.

• Fairness Opinion on Reduced Offer

  Duff & Phelps, the Special Committee's financial advisor, rendered an opinion on April 28, 2026, stating that the $0.066 per share merger consideration is fair from a financial point of view to unaffiliated shareholders. The analysis noted that the company's enterprise value is insufficient to cover its debt and liabilities, resulting in a negative equity value before applying an option value analysis.

• High Likelihood of Shareholder Approval

  The buyer group, comprising rollover shareholders, collectively owns approximately 53.35% of the company's voting power and has committed to vote in favor of the merger. This makes it highly probable that the transaction will receive the necessary two-thirds shareholder approval.

auto_awesomeAnalysis

This SC 13E3/A filing provides the definitive disclosure for LakeShore Biopharma's amended going-private transaction, confirming a significantly reduced per-share consideration of $0.066. This represents a drastic reduction from the initial offer of $0.90 per share, primarily driven by approximately RMB576.5 million (US$84.3 million) in arbitral awards, which substantially exceed the company's current equity value. While the offer provides liquidity to unaffiliated shareholders, it reflects severe financial distress and a significantly diminished valuation. The fairness opinion from Duff & Phelps acknowledges that the company's enterprise value is insufficient to cover its debt and liabilities, with equity value being negative before applying an option value analysis. The transaction is highly likely to be approved due to the buyer group's committed voting power (53.35% of outstanding shares). This event marks a critical, negative turning point for public shareholders, as the company will cease to be publicly traded at a distressed valuation.